These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32139007)

  • 1. Multiple myeloma: Current advances and future directions.
    Ola Landgren C
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101155. PubMed ID: 32139007
    [No Abstract]   [Full Text] [Related]  

  • 2. Modern treatments and future directions for newly diagnosed multiple myeloma patients.
    Lu SX
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101151. PubMed ID: 32139016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
    Kunacheewa C; Manasanch EE
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconstructing the evolutionary history of multiple myeloma.
    Maura F; Rustad EH; Boyle EM; Morgan GJ
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101145. PubMed ID: 32139011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
    Rustad EH; Boyle EM
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
    Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
    Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
    [No Abstract]   [Full Text] [Related]  

  • 7. Myeloma and related disorders.
    Kyle RA; Durie BG; Boccadoro M; Pavlovsky S
    Rev Invest Clin; 1994 Apr; Suppl():46-51. PubMed ID: 7886308
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple myeloma: how far have we come?
    Anderson KC
    Mayo Clin Proc; 2003 Jan; 78(1):15-7. PubMed ID: 12528872
    [No Abstract]   [Full Text] [Related]  

  • 9. [Not Available].
    Hitz F
    Praxis (Bern 1994); 2016; 105(21):1255-1260. PubMed ID: 28573955
    [No Abstract]   [Full Text] [Related]  

  • 10. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.
    Martinez-Lopez J; Sanchez-Vega B; Barrio S; Cuenca I; Ruiz-Heredia Y; Alonso R; Rapado I; Marin C; Cedena MT; Paiva B; Puig N; Mateos MV; Ayala R; Hernández MT; Jimenez C; Rosiñol L; Martínez R; Teruel AI; Gutiérrez N; Martin-Ramos ML; Oriol A; Bargay J; Bladé J; San-Miguel J; Garcia-Sanz R; Lahuerta JJ
    Leukemia; 2017 Jun; 31(6):1446-1449. PubMed ID: 28210002
    [No Abstract]   [Full Text] [Related]  

  • 11. Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons.
    Avet-Loiseau H
    Am Soc Clin Oncol Educ Book; 2016; 35():e425-30. PubMed ID: 27249750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of minimal residual disease in myeloma and the need for a consensus approach.
    Rawstron AC; Paiva B; Stetler-Stevenson M
    Cytometry B Clin Cytom; 2016 Jan; 90(1):21-5. PubMed ID: 26202864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma.
    Saburi M; Ogata M; Soga Y; Kondo Y; Kurimoto R; Itani K; Kohno K; Uchida H; Nakayama T
    J Clin Exp Hematop; 2020; 60(1):17-20. PubMed ID: 32224561
    [No Abstract]   [Full Text] [Related]  

  • 14. Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol.
    Pileri A; Barbui T; Boccadoro M; Comotti B; Dammacco F; Gallamini A; Marmont F; Neretto G; Petrucci MT; Resegotti L
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():168-9. PubMed ID: 2713554
    [No Abstract]   [Full Text] [Related]  

  • 15. [Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma].
    Schleiffenbaum BE
    Praxis (Bern 1994); 2012 Nov; 101(24):1521-9; quiz 1530-1. PubMed ID: 23184544
    [No Abstract]   [Full Text] [Related]  

  • 16. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance therapy in multiple myeloma.
    Kumar S
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):133-4. PubMed ID: 24892259
    [No Abstract]   [Full Text] [Related]  

  • 18. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
    Diamond B; Maclachlan K; Chung DJ; Lesokhin AM; Ola Landgren C
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101140. PubMed ID: 32139006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.
    Weinhold N; Kirn D; Seckinger A; Hielscher T; Granzow M; Bertsch U; Egerer G; Salwender H; Blau IW; Weisel K; Hillengass J; Raab MS; Hose D; Goldschmidt H; Jauch A
    Haematologica; 2016 Mar; 101(3):e116-9. PubMed ID: 26611471
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.